278 related articles for article (PubMed ID: 21960245)
1. Long-term transfusion independence in del(5q) MDS patients who discontinue lenalidomide.
Giagounidis AA; Kulasekararaj A; Germing U; Radkowski R; Haase S; Petersen P; Göhring G; Büsche G; Aul C; Mufti GJ; Platzbecker U
Leukemia; 2012 Apr; 26(4):855-8. PubMed ID: 21960245
[No Abstract] [Full Text] [Related]
2. Long-term transfusion independence in del(5q) MDS patients after short term therapy with lenalidomide: 2 new cases.
Himmelmann A; Tchinda J
Leuk Res; 2012 May; 36(5):656-7. PubMed ID: 22177945
[No Abstract] [Full Text] [Related]
3. Morphologic analysis in myelodysplastic syndromes with del(5q) treated with lenalidomide. A Japanese multiinstitutional study.
Matsuda A; Taniwaki M; Jinnai I; Harada H; Watanabe M; Suzuki K; Yanagita S; Suzuki T; Yoshida Y; Kimura A; Tsudo M; Tohyama K; Takatoku M; Ozawa K
Leuk Res; 2012 May; 36(5):575-80. PubMed ID: 22172461
[TBL] [Abstract][Full Text] [Related]
4. Lenalidomide in lower-risk myelodysplastic syndromes with karyotypes other than deletion 5q and refractory to erythropoiesis-stimulating agents.
Sibon D; Cannas G; Baracco F; Prebet T; Vey N; Banos A; Besson C; Corm S; Blanc M; Slama B; Perrier H; Fenaux P; Wattel E;
Br J Haematol; 2012 Mar; 156(5):619-25. PubMed ID: 22211483
[TBL] [Abstract][Full Text] [Related]
5. A delayed yet durable response to very short lenalidomide therapy and unexpected clone redistribution in a case of myelodysplastic syndrome with del(5q) and del(20q).
Xu F; Li X; Chang C; He Q; Zhang Z; Zhang Q; Wu L
Leuk Res; 2009 Nov; 33(11):e199-202. PubMed ID: 19592091
[No Abstract] [Full Text] [Related]
6. The role of lenalidomide in the management of myelodysplasia with del 5q.
Kelaidi C; Eclache V; Fenaux P
Br J Haematol; 2008 Feb; 140(3):267-78. PubMed ID: 18217896
[TBL] [Abstract][Full Text] [Related]
7. Sudden acute leukemia transformation in a MDS patient with del(5q) in complete cytogenetic remission after lenalidomide.
Breccia M; Cannella L; Latagliata R; Nanni M; Santopietro M; Loglisci G; Ferretti A; Barzotti R; Oliva EN; Alimena G
Leuk Res; 2011 Jun; 35(6):e69-70. PubMed ID: 21232796
[No Abstract] [Full Text] [Related]
8. Pleiotropic mechanisms of action of lenalidomide efficacy in del(5q) myelodysplastic syndromes.
Heise C; Carter T; Schafer P; Chopra R
Expert Rev Anticancer Ther; 2010 Oct; 10(10):1663-72. PubMed ID: 20942636
[TBL] [Abstract][Full Text] [Related]
9. Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletion--the GFM experience.
Le Bras F; Sebert M; Kelaidi C; Lamy T; Dreyfus F; Delaunay J; Banos A; Blanc M; Vey N; Schmidt A; Visanica S; Eclache V; Turlure P; Beyne-Rauzy O; Guerci A; Delmer A; de Botton S; Rea D; Fenaux P; Adès L
Leuk Res; 2011 Nov; 35(11):1444-8. PubMed ID: 21715006
[TBL] [Abstract][Full Text] [Related]
10. Lenalidomide--a transforming therapeutic agent in myelodysplastic syndromes.
List A
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S302-4. PubMed ID: 19778857
[TBL] [Abstract][Full Text] [Related]
11. Lenalidomide in del 5q MDS: responses and side effects revisited.
Tiu RV; Sekeres MA
Leuk Res; 2011 Nov; 35(11):1440-1. PubMed ID: 21764127
[No Abstract] [Full Text] [Related]
12. Patients with del(5q) MDS who fail to achieve sustained erythroid or cytogenetic remission after treatment with lenalidomide have an increased risk for clonal evolution and AML progression.
Göhring G; Giagounidis A; Büsche G; Kreipe HH; Zimmermann M; Hellström-Lindberg E; Aul C; Schlegelberger B
Ann Hematol; 2010 Apr; 89(4):365-74. PubMed ID: 19855965
[TBL] [Abstract][Full Text] [Related]
13. Telomere shortening, clonal evolution and disease progression in myelodysplastic syndrome patients with 5q deletion treated with lenalidomide.
Göhring G; Lange K; Hofmann W; Nielsen KV; Hellström-Lindberg E; Roy L; Morgan M; Kreipe H; Büsche G; Giagounidis A; Schlegelberger B
Leukemia; 2012 Feb; 26(2):356-8. PubMed ID: 21799512
[No Abstract] [Full Text] [Related]
14. Efficacy of lenalidomide in a patient with myelodysplastic syndrome with isolated del(5q) and JAK2V617F mutation.
Nomdedeu M; Maffioli M; Calvo X; Martínez-Trillos A; Baumann T; Díaz-Beyá M; Aguilar JL; Rozman M; Costa D; Esteve J; Cervantes F; Colomer D; Nomdedeu B
Leuk Res; 2011 Sep; 35(9):1276-8. PubMed ID: 21764129
[No Abstract] [Full Text] [Related]
15. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
Nimer SD
J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
[TBL] [Abstract][Full Text] [Related]
16. Lenalidomide for del(5q) and non-del(5q) myelodysplastic syndromes.
Giagounidis AA
Semin Hematol; 2012 Oct; 49(4):312-22. PubMed ID: 23079061
[TBL] [Abstract][Full Text] [Related]
17. Role of lenalidomide in the treatment of myelodysplastic syndromes.
Komrokji RS; List AF
Semin Oncol; 2011 Oct; 38(5):648-57. PubMed ID: 21943671
[TBL] [Abstract][Full Text] [Related]
18. The difficulty to define progression patterns in patients with early stage myelodysplastic syndromes and deletion 5q--new prognostic markers are needed.
Kuendgen A
Leuk Res; 2014 Mar; 38(3):287-8. PubMed ID: 24433864
[No Abstract] [Full Text] [Related]
19. Haematological and cytogenetic responses after only 7 days of Lenalidomide in a patient with myelodysplastic syndrome and chromosome 5q deletion.
Hadiji Mseddi S; Kallel F; Kassar O; Elloumi M; Jedidi I; Sennana H; Fenaux P
Leuk Res; 2011 Sep; 35(9):e175-6. PubMed ID: 21658768
[No Abstract] [Full Text] [Related]
20. Lenalidomide in the context of complex karyotype or interrupted treatment: case reviews of del(5q)MDS patients with unexpected responses.
Giagounidis AA; Haase S; Heinsch M; Göhring G; Schlegelberger B; Aul C
Ann Hematol; 2007 Feb; 86(2):133-7. PubMed ID: 17111142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]